Cocrystal Pharma Inc. has released a presentation outlining its progress in developing antiviral drug candidates targeting high-value markets, including influenza, norovirus, and coronaviruses. The company highlights its proprietary structure-based drug discovery platform, which leverages Nobel Prize-winning technology to accelerate the identification and optimization of novel, broad-spectrum antivirals. Clinical assets such as the oral norovirus/coronavirus protease inhibitor CDI-988 and the oral influenza PB2 inhibitor CC-42344 have demonstrated favorable Phase 1 results, with further studies planned. The presentation also notes ongoing efforts to secure government contracts related to pandemic preparedness and emphasizes cost-efficient operations with no debt. You can access the full presentation through the link below. https://www.cocrystalpharma.com